

1381 13 FEB 27 A9:22

**ATTORNEYS AT LAW**

WASHINGTON HARBOUR  
3000 K STREET, N.W.  
6TH FLOOR  
WASHINGTON, D.C. 20007-5109  
202.672.5300 TEL  
202.672.5399 FAX  
foley.com

WRITER'S DIRECT LINE  
202.672.5430  
drosen@foley.com EMAIL

February 26, 2013

**VIA FEDERAL EXPRESS**

Dockets Management Branch  
Food and Drug Administration  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**CITIZEN PETITION**

Foley & Lardner LLP (the "Petitioner") submits this Petition under the provisions of section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act and 21 CFR §§ 10.30, 314.93 and 314.161 requesting that the Commissioner of Food and Drugs issue a determination that Cytoxan® for Injection, originally approved by FDA as a lyophilized powder under NDA 12-142 was not withdrawn for reasons related to safety or effectiveness.

**A. Action Requested**

This petition requests FDA to determine whether Cytoxan for Injection, originally approved by FDA as a lyophilized powder under NDA 12-142 has been voluntarily withdrawn from sale for safety or effectiveness reasons.

**B. Statement of Grounds**

I. The above-referenced drug product, Cytoxan (cyclophosphamide) for Injection NDA # 12-142, was originally approved on November 16, 1959. The product was approved as a dry powder form which included sodium chloride.

2013-1460

CP

FDA-2013-P-0241

II. On January 4, 1984, Bristol obtained approval for a new formulation, cyclophosphamide lyophilized (which included mannitol in the formulation), under NDA 12-142 (supplement number 058). Bristol discontinued marketing of the Cytosan sodium chloride powder product in 1997.

III. On November 7, 2003, Bristol obtained approval for the current dry powder formulation (cyclophosphamide alone) and discontinued sale of the lyophilized product. The Petitioner knows of no information or documentation that establishes that the lyophilized formulation was voluntarily withdrawn from sale for reasons of safety or efficacy. This product is now currently marketed by Baxter Healthcare.

IV. On March 1, 2004, FDA determined that the Cytosan sodium chloride powder product was not withdrawn from sale reasons of safety or efficacy (see FDA Docket No. 01P-0333). Generic ready to use solution and lyophilized cyclophosphamide products were approved and subsequently discontinued from the market.

V. Under FDA regulations, an abbreviated new drug application ("ANDA") seeking approval of a generic product referencing a discontinued product must be accompanied by a Citizen Petition for FDA's determination that the discontinued reference listed drug was not voluntarily withdrawn for safety or efficacy reasons.

#### **C. Environmental Impact**

The Petitioner claims a categorical exclusion under 21 CFR § 25.31.

#### **D. Economic Impact**

By allowing the submission and filing of an ANDA for a Cyclophosphamide for Injection lyophilized formulation, the public will be afforded access to a, high quality, lower cost, therapeutically equivalent version of the reference listed drug. Having another formulation, i.e., a lyophilized form will also help ensure that there are alternative products available in the event that there is a drug shortage associated with the dry powder formulations.

**E. Certification**

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this Petition includes all information and views on which the Petition relies, and that it includes representative data and information known to the Petitioner which are unfavorable to the Petition.

A handwritten signature in blue ink that reads "David L. Rosen". The signature is fluid and cursive, with the first name "David" and last name "Rosen" clearly distinguishable.

---

David L. Rosen, B.S. Pharm., J.D.  
Foley & Lardner LLP  
3000 K Street, NW, 6<sup>th</sup> Floor  
Washington, DC 20007-5143  
(202) 672-5430  
(202) 672-5399 (fax)

From: (202) 672-5300  
David Rosen  
Foley & Lardner LLP  
3000 K Street NW  
Suite 600  
Washington, DC 20007

Origin ID: ZRZA




J13101212190326

SHIP TO: (301) 827-6860

BILL SENDER

**Dockets Management Branch**  
**Food and Drug Admin. / DHHS**  
**5630 Fishers Ln Rm 1061**

**Rockville, MD 20857**



Ship Date: 26FEB13  
ActWgt: 0.5 LB  
CAD: 103789639/WSX12500

Delivery Address Bar Code



Ref # 099672-0101-9087  
Invoice #  
PO #  
Dept #

TRK# 7948 4177 7656  
0201

WED - 27 FEB 10:30A  
PRIORITY OVERNIGHT

DSR  
20857  
MD-US  
IAD

**19 NSFA**



Align top of FedEx Express® shipping label here

neutral  
printing